Big Data Governance: Solidarity and the Patient Voice

Part of the Law, Governance and Technology Series book series (LGTS, volume 29)

Abstract

Rare diseases are individually rare but collectively form a population of 30 million people within Europe alone. Most rare diseases are genetic in origin and recent research initiatives are bringing the latest genetic technologies, including whole genome sequencing, together with medical records and natural history data. The rareness of these conditions means that strategies for data sharing are a necessity to ensure that patients are able to obtain a diagnosis and the potential for treatment. Rare disease research is therefore a preeminent example of biomedical “Big Data”. This chapter explores the social and ethical challenges of biomedical “Big Data” with a focus on two case studies of contemporary rare disease research and through the framework of “solidarity” as developed by Prainsack and Buyx (2011, 2013). The analysis presented in this chapter is sympathetic to the concept of solidarity as the basis for a governance model for biomedical “Big Data” research. However there are some limitations to the solidarity model and it is argued here that a presumption of solidarity may presume too much. The principle of solidarity is very evident within the history of rare disease patient activism but this has evolved alongside other practices, characterised here as “the patient voice” which demands a more collaborative approach to the governance of research. The collaborative approach is one which allows the patient voice to be heard and respected thereby giving research participants an opportunity to be able to negotiate the conditions of participation in research. The chapter concludes with some reflections upon the future challenges for biomedical “Big Data” governance.

References

  1. American College of Medical Genetics. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine 15(7): 565–578.CrossRefGoogle Scholar
  2. American College of Medical Genetics. 2015. ACMG policy statement: Updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genetics in Medicine 17(1): 68–69.CrossRefGoogle Scholar
  3. Andersen, T. 2012. The political empowerment of rare disease patient advocates both at EU and national level. Orphanet Journal of Rare Diseases 7(2): 1–3.Google Scholar
  4. Árnason, E. and B. Andersen. 2013. deCODE and Iceland: A critique. eLS. doi: 10.1002/9780470015902.a0005180.pub20. Published online: 15 FEB 2013.
  5. Aymé, S., A. Kole, and S. Groft. 2008. Empowerment of patients: Lessons from the rare diseases community. Lancet 371(9629): 2048–2051.CrossRefGoogle Scholar
  6. Bathe, O.F., and A.L. McGuire. 2009. The ethical use of existing samples for genome research. Genetics in Medicine 11: 712–715.CrossRefGoogle Scholar
  7. Boycott, K.M., M.R. Vanstone, D.E. Bulman, and A.E. Mackenzie. 2013. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14: 681–691. doi:10.1038/nrg3555.CrossRefGoogle Scholar
  8. Callon, M., and V. Rabeharisoa. 2003. Research “in the wild” and the shaping of new social identities. Technology in Society 25(2):193–204.Google Scholar
  9. Cassell, J., and A. Young. 2002. Why we should not seek individual informed consent for participation in health services research. Journal of Medical Ethics 28(5): 313–317. doi:10.1136/jme.28.5.313.CrossRefGoogle Scholar
  10. Department of Health. 2003. Our inheritance our future. London: The Stationery Office.Google Scholar
  11. Department of Health. 2011. Taking stock of regenerative medicine. London: The Stationery Office.Google Scholar
  12. Department of Health. 2014. The government response to the Mid Staffordshire NHS foundation trust public inquiry. London: The Stationery Office.Google Scholar
  13. Dresser, R. 2001. When science offers salvation. Patient advocacy and ethics. Oxford: Oxford University Press.Google Scholar
  14. Epstein, S. 1995. The construction of lay expertise – AIDS activism and the forging of credibility in the reform of clinical trials. Science, Technology & Human Values 20: 408–437.CrossRefGoogle Scholar
  15. Genetic Alliance UK. 2015. Genome sequencing: what do patients think? patient charter. London: Genetic Alliance UK.Google Scholar
  16. Hansson M. G, H. Lochmüller, O. Riess, F. Schaefer, M. Orth, Y. Rubinstein, C. Molster, H. Dawkins, D. Taruscio, M. Posada, S. Woods. 2016. The risk of re-identification versus the need to identify individuals in rare disease research. European Journal of Human Genetics 1–6.Google Scholar
  17. Houyez, F. 2004. Active involvement of patients in drug research, evaluation, and commercialization: European perspective. The Journal of Ambulatory Care Management 27(2): 139–145.CrossRefGoogle Scholar
  18. Hoeyer, K. 2010. Donors perceptions of consent to and feedback from biobank research: Time to acknowledge diversity? Public Health Genomics 13: 345–352.CrossRefGoogle Scholar
  19. International Rare Disease Research Consortium (IRDiRC). 2015. http://www.irdirc.org/goals/ Accessed 28 Oct 2015.
  20. Kaye, J., L. Curren, N. Anderson, K. Edwards, S.M. Fullerton, et al. 2012a. From patients to partners: Participant-centric initiatives in biomedical research. Nature Reviews Genetics 13: 371–376.CrossRefGoogle Scholar
  21. Kaye, J., S.M.C. Gibbons, C. Heeney, M. Parker, and A. Smart. 2012b. Governing biobanks: Understanding the interplay between law and practice. London: Bloomsbury.Google Scholar
  22. Knoppers, B.M. 2014. International ethics harmonization and the global alliance for genomics and health. Genome Medicine 6(2): 13.CrossRefGoogle Scholar
  23. Kymlicka, W. 1990. Contemporary political philosophy: an introduction. Oxford: Clarendon Press the University of Michigan.Google Scholar
  24. Levitt, M., and S. Weldon. 2005. A well placed trust? public perceptions of the governance of DNA databases. Crit Public Health 15(4): 311–321. doi:10.1080/09581590500523186.CrossRefGoogle Scholar
  25. Little L. 2015. Care.data loose ends need tying up now. Opinion. Health Service Journal. http://www.hsj.co.uk/comment/caredata-loose-ends-need-tying-up-now/5085349.article Accessed 12 Oct 2015.
  26. Lupton, D., et al. 1991. Caveat emptor or blissful ignorance? Patients and the consumerist ethos. Social Science and Medicine 33: 559–568.CrossRefGoogle Scholar
  27. Mascalzoni D, E. Dove, Y. Rubinstein, H. Dawkins, A. Kole, P. McCormack, S. Woods, O. Riess, F. Schaefer, H. Lochmüller, B. Knoppers, M. Hansson. 2014. International charter of principles for sharing bio-specimens and data. European Journal of Human Genetics. 23(6): 721–728.Google Scholar
  28. Mascalzoni, D., E. Dove, Y. Rubinstein, H. Dawkins, A. Kole, P. McCormack, S. Woods, O. Riess, F. Schaefer, H. Lochmüller, B. Knoppers, and M. Hansson. 2015. International charter of principles for sharing bio-specimens and data. European Journal of Human Genetics 23: 721–728. doi:10.1038/ejhg.2014.197.
  29. Mavris, M., and Y. Le Cam. 2012. Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Molecular Syndromology 3(5): 237–243. doi:10.1159/000342758.Google Scholar
  30. McCormack, P, A. Kole, S. Gainotti, D. Mascalzoni, C. Molster, H. Lochmüller, S. Woods. 2016. “You should at least ask”. The views of rare disease patients and advocates on large scale systems for data and biosample sharing. European Journal of Human Genetics. doi:10.1038/ejhg.2016.30.
  31. Mittelstadt, B.D., and L. Floridi. 2016. The ethics of big data: Current and foreseeable issues in biomedical contexts. Science and Engineering Ethics 22(2): 303–341. doi:10.1007/s11948-015-9652-2.
  32. Nightingale, P., and P. Martin. 2004. The myth of the biotech revolution. Trends in Biotechnology 22(11): 564–569.CrossRefGoogle Scholar
  33. O’Neill, O. 2002. Autonomy and trust in bioethics. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
  34. Parker, M., R. Ashcroft, A.O.M. Wilkie, and A. Kent. 2004. Ethical review of research into rare genetic disorders. BMJ 329: 288.CrossRefGoogle Scholar
  35. Plows, A. 2010. Debating human genetics: Contemporary issues in public policy and ethics. New York: Routledge.Google Scholar
  36. Prainsack, B., and A. Buyx. 2011. Solidarity: reflections on an emerging concept in bioethics. Swindon: Nuffield Council on Bioethics.Google Scholar
  37. Prainsack, B., and A. Buyx. 2013. A solidarity-based approach to the governance of research biobanks. Medical Law Review 21(1): 71–91. doi:10.1093/medlaw/fws040.CrossRefGoogle Scholar
  38. Rabeharisoa, V. 2003. The struggle against neuromuscular diseases in France and the emergence of the “partnership model” of patient organisation. Social Science and Medicine 57: 2127–2136.CrossRefGoogle Scholar
  39. Rabeharisoa, V. 2006. From representation to mediation: The shaping of collective mobilization on muscular dystrophy in France. Social Science and Medicine 62: 564–576.CrossRefGoogle Scholar
  40. Redfern Report. 2001. The report of The Royal Liverpool Children's Inquiry. London: The Stationery Office. http://www.rlcinquiry.org.uk/
  41. Rodwin, M.A. 1994. Patient accountability and quality of care: lessons from medical consumerism and the patients’ rights, women’s health and disability rights movements. Am J Law Med 20: 147–167.Google Scholar
  42. Rose, N., and C. Novas. 2005. Biological citizenship. In Global assemblages: Technology, politics and ethics as anthropological problems, ed. A. Ong and S.J. Collier, 439–463. Oxford: Blackwell.Google Scholar
  43. Ruzek, S. 2007. Transforming doctor-patient relationships. Journal of Health Services Research & Policy 12: 181–182.CrossRefGoogle Scholar
  44. Schieppati, A., et al. 2008. Why rare diseases are an important medical and social issue. Lancet 371(9629): 2039–2041.CrossRefGoogle Scholar
  45. Sheehan, M. 2011. Can broad consent be informed consent? Public Health Ethics 4(3): 226–235.CrossRefGoogle Scholar
  46. Solbakk, J.H., S. Holm, and B. Hofmann. 2009. The ethics of research biobanking. Dordrecht: Springer.CrossRefGoogle Scholar
  47. Steinsbekk, K.S, B. Kåre, K. Myskja, B. Solberg. 2013. Broad consent versus dynamic consent in biobank research: Is passive participation an ethical problem? European Journal of Human Genetics 21:897–902. doi:10.1038/ejhg.2012.282; published online 9 Jan 2013.
  48. TREAT-NMD Global Database Oversight Committee (TGDOC). http://www.treat-nmd.eu/resources/patient-registries/global-registries/governance
  49. Tutton, R., and O. Corrigan. 2004. Genetic databases: Socio-ethical issues in the collection and use of DNA. London: Routledge.Google Scholar
  50. Waldby C (2011) Citizenship, labor and the biopolitics of the bioeconomy: Recruiting female tissue donors for stem-cell research. Scholar & Feminist Online Spring 9.1/9.2: special double issue Critical Conceptions: 9 Technology, Justice, and the Global Reproductive Market.Google Scholar
  51. Wolf, S.M., B.N. Crock, B. Van Ness, et al. 2012. Managing incidental findings and research results in genomic research involving biobanks & archived datasets. Genetics in Medicine: Official Journal of the American College of Medical 14(4): 361–384. doi:10.1038/gim.2012.23.
  52. Woods, S., and P. McCormack. 2013. Disputing the ethics of research: The challenge from bioethics and patient activism to the interpretation of the declaration of Helsinki in clinical trials. Bioethics 27(5): 243–250.CrossRefGoogle Scholar
  53. World Medical Association Declaration of Helsinki. 2013. Ethical principles for medical research involving human subjects. Ferney-Voltaire: World Medical Association.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Policy Ethics and Life Sciences Research Centre Claremont Bridge (4th Floor)Newcastle UniversityNewcastle upon TyneUK

Personalised recommendations